110 related articles for article (PubMed ID: 8993553)
21. Protein phosphorylation by peroxisome proliferators: species-specific stimulation of protein kinases and its role in PP-induced transcriptional activation.
Motojima K; Passilly P; Jannin B; Latruffe N
Ann N Y Acad Sci; 1996 Dec; 804():413-23. PubMed ID: 8993560
[No Abstract] [Full Text] [Related]
22. Hepatic peroxisome proliferation: induction by BR-931, a hypolipidemic analog of WY-14,643.
Reddy JK; Azarnoff DL; Sirtori CR
Arch Int Pharmacodyn Ther; 1978 Jul; 234(1):4-14. PubMed ID: 708142
[TBL] [Abstract][Full Text] [Related]
23. Comparative and simultaneous effects of simvastatin and ciprofibrate on plasma lipid parameters and upon hepatic drug metabolizing and peroxisome proliferation marker enzymes in the male Wistar rat.
Charmoillaux M; Goudonnet H; Mercenne F; Mounié J; Truchot RC
Cell Mol Biol; 1991; 37(8):765-71. PubMed ID: 1807786
[TBL] [Abstract][Full Text] [Related]
24. Potent peroxisome proliferators inhibit beta-oxidation in the isolated perfused rat liver.
Bojes HK; Thurman RG
Toxicol Appl Pharmacol; 1996 Oct; 140(2):322-7. PubMed ID: 8887448
[TBL] [Abstract][Full Text] [Related]
25. Common structural requirements for peroxisome proliferation by tetrazole and carboxylic acid-containing compounds.
Eacho PI; Foxworthy PS; Lawrence JW; Herron DK; Noonan DJ
Ann N Y Acad Sci; 1996 Dec; 804():387-402. PubMed ID: 8993558
[No Abstract] [Full Text] [Related]
26. Effects of joint exposures to selected peroxisome proliferators on hepatic acyl-CoA oxidase activity in male B6C3F1 mice.
Ochs JB; Baldwin LA; Leonard DA; Calabrese EJ
Hum Exp Toxicol; 1992 Mar; 11(2):83-8. PubMed ID: 1349224
[TBL] [Abstract][Full Text] [Related]
27. Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans.
Reddy JK; Lalwai ND
Crit Rev Toxicol; 1983; 12(1):1-58. PubMed ID: 6360536
[TBL] [Abstract][Full Text] [Related]
28. Short-term inhibition of fatty acid and cholesterol biosynthesis by the lipid-lowering drug gemfibrozil in primary rat hepatocyte cultures and rat liver in vivo.
Hemingway CJ; Tey KK; Munday MR
Biochem Soc Trans; 1995 Aug; 23(3):496S. PubMed ID: 8566397
[No Abstract] [Full Text] [Related]
29. Receptor-mediated mechanisms of peroxisome proliferators.
Green S
Biochem Pharmacol; 1992 Feb; 43(3):393-401. PubMed ID: 1311577
[No Abstract] [Full Text] [Related]
30. Hepatic effects of some [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY-14,643) analogs in the mouse.
Reddy JK; Moody DE; Azarnoff DL; Tomarelli RM
Arch Int Pharmacodyn Ther; 1977 Jan; 225(1):51-7. PubMed ID: 851495
[TBL] [Abstract][Full Text] [Related]
31. Hypolipidemic effect of peroxisome proliferators. Transcriptional suppression of apolipoprotein C-III.
Hertz R; Bishara-Shieban J; Bar-Tana J
Ann N Y Acad Sci; 1996 Dec; 804():731-3. PubMed ID: 8993607
[No Abstract] [Full Text] [Related]
32. Long-term effects of hypolipidemic peroxisome proliferator administration on hepatic hydrogen peroxide metabolism in rats.
Tamura H; Iida T; Watanabe T; Suga T
Carcinogenesis; 1990 Mar; 11(3):445-50. PubMed ID: 2311188
[TBL] [Abstract][Full Text] [Related]
33. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens.
Reddy JK; Azarnoff DL; Hignite CE
Nature; 1980 Jan; 283(5745):397-8. PubMed ID: 6766207
[No Abstract] [Full Text] [Related]
34. Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes -- role of the peroxisome proliferator-activated receptor-alpha.
Kockx M; Princen HM; Kooistra T
Thromb Haemost; 1998 Dec; 80(6):942-8. PubMed ID: 9869165
[TBL] [Abstract][Full Text] [Related]
35. Review of the hepatic response to hypolipidaemic drugs in rodents and assessment of its toxicological significance to man.
Cohen AJ; Grasso P
Food Cosmet Toxicol; 1981 Oct; 19(5):585-605. PubMed ID: 7030887
[No Abstract] [Full Text] [Related]
36. Method for determining whether the number of hepatocytes in rat liver is increased after treatment with the peroxisome proliferator gemfibrozil.
Carthew P; Maronpot RR; Foley JF; Edwards RE; Nolan BM
J Appl Toxicol; 1997; 17(1):47-51. PubMed ID: 9048227
[TBL] [Abstract][Full Text] [Related]
37. Peroxisome proliferators induce mouse liver stearoyl-CoA desaturase 1 gene expression.
Miller CW; Ntambi JM
Proc Natl Acad Sci U S A; 1996 Sep; 93(18):9443-8. PubMed ID: 8790349
[TBL] [Abstract][Full Text] [Related]
38. Increased response to peroxisomal proliferators in starved rats.
Hertz R; Bar-Tana J
Biochim Biophys Acta; 1987 Jan; 917(1):57-61. PubMed ID: 3790611
[TBL] [Abstract][Full Text] [Related]
39. Toxicological evaluation of peroxisome proliferators. Further cellular and molecular aspects.
Passilly P; Pacot C; Jannin B; Cherkaoui Malki M; Bardot O; Caira F; Clemencet MC; Latruffe N
Ann N Y Acad Sci; 1996 Dec; 804():716-8. PubMed ID: 8993603
[No Abstract] [Full Text] [Related]
40. Peroxisome proliferator-activated receptor alpha required for gene induction by dehydroepiandrosterone-3 beta-sulfate.
Peters JM; Zhou YC; Ram PA; Lee SS; Gonzalez FJ; Waxman DJ
Mol Pharmacol; 1996 Jul; 50(1):67-74. PubMed ID: 8700121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
